

The p50 NF- κ B subunit is a prognostic regulator of colorectal cancer-associated inflammation

Chiara Porta¹, Alessandro Ippolito¹, Francesca Maria Consonni¹, Lorenzo Carraro¹, Giuseppe Celesti², Fabio Grizzi², Fabio Pasqualini², Silvia Tartari², Luigi Laghi², Antonio Sica^{1,2}

¹Department of Pharmaceutical Sciences, Università del Piemonte Orientale “Amedeo Avogadro”, Novara, Italy;

²Humanitas Clinical and Research Center, Rozzano, Italy;

In most tumors, tumor associated macrophages (TAMs) express an M2-skewed phenotype and are therefore associated with unfavorable prognosis. However, the impact of TAMs in colorectal cancer (CRC) development and outcome is still controversial. We first demonstrate, by parallel studies in colitis-associated cancer (CAC) and in genetically driven *Apc*^{Min} mouse models, that p50 NF- κ B is essential for CRC development by restraining M1-dependent antitumor response. In absence of p50 mice developed fewer and smaller CRC lesions which express enhanced levels of M1/Th1 cytokines/chemokines including IL-12 and CXCL10, whose administration restrained CAC development *in vivo*. Moreover colons from p50^{-/-} tumor bearers showed a reduced number of TAMs, as opposed to increased NK, NKT, CD8⁺ T cells and apoptotic cancer cells. Consistently, in CRC patients, high burden of p50⁺ TAMs was associated with decreased M1/Th1 inflammation and worse outcome indicating p50 as a new candidate for prognostic and target therapeutic intervention.